Related references
Note: Only part of the references are listed.
Editorial Material
Infectious Diseases
Noah Kojima et al.
LANCET INFECTIOUS DISEASES
(2022)
Editorial Material
Medicine, General & Internal
Eric J. Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Barbra A. Dickerman et al.
Summary: The mRNA vaccines BNT162b2 and mRNA-1273 showed high efficacy in preventing COVID-19 infection, hospitalization, and death among nearly 440,000 veterans observed in the study. There was a 21% lower risk of infection with mRNA-1273 compared to BNT162b2. The study covered periods when either the alpha or delta variants of the virus were dominant.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Laith J. Abu-Raddad et al.
Summary: This study aimed to assess the protection against breakthrough infection with SARS-CoV-2 after mRNA vaccination, comparing individuals with and without prior infection. The findings showed that individuals with prior SARS-CoV-2 infection had a significantly lower risk for breakthrough infection, indicating a potential benefit of natural immunity in vaccine protection.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Eric J. Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Ronen Arbel et al.
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Eric J. Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Multidisciplinary Sciences
Adam Booth et al.
Summary: The study aims to analyze various clinical, demographic, and lifestyle variables associated with specific adverse outcomes in COVID-19 patients; by combining data from 17,860,001 patients across 14 countries, it identified many risk factors related to COVID-19, including age over 75, male sex, severe obesity, and active cancer.
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.
Article
Multidisciplinary Sciences
Leonidas Stamatatos et al.
Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.
Article
Medicine, General & Internal
Noam Barda et al.
Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Jose Vitale et al.
Summary: This cohort study investigates the rate of SARS-CoV-2 reinfection among individuals in Lombardy, Italy, who had previously recovered from COVID-19.
JAMA INTERNAL MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Alyson M. Cavanaugh et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, Research & Experimental
Alessio Mazzoni et al.
Summary: The study suggests that COVID-19-recovered individuals may not need a second vaccine dose to further enhance immune response, while naive individuals require a second dose for increased immunity. This indicates that redirecting vaccine doses from COVID-19-recovered individuals to naive individuals could shorten the time to achieve herd immunity.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Medicine, General & Internal
Laith J. Abu-Raddad et al.
Summary: The study shows that reinfection is rare in Qatar's young and international population, with natural infection providing strong protection against reinfection with an estimated efficacy of around 95% for at least seven months. Reinfections are often less severe than primary infections.
